Appeals Rulings Signal Punishment is Easing for Big Tobacco

  5/26/2015 Perhaps no industry besides investment banks has been hit as hard by the federal court system than tobacco over the past several years. A pair of recent appeals rulings, however, indicates a substantial turn in the industry’s decades-long financial flogging. On Friday, the D.C. Court of Appeals delivered a mixed-ruling, in which some


More Cable Consolidation as Charter buys Time Warner

5/26/2015 Charter Communications is expected to announce on Tuesday that the company has reached an agreement to purchase Time Warner Cable. If the deal passes regulatory scrutiny, the third and second largest cable providers, respectively, will provide heavy competition to industry leader Comcast, as well as other companies like DirecTV and Netflix. The estimated $55


Banks: Target, Mastercard Data Breach Settlement is Insufficient

5/25/2015 A lawsuit will continue in U.S. District Court in Minnesota regarding Target’s widespread 2013 pre-holiday data breach as banks rejected a $19 million settlement proposed last month. Over 40 million debit and credit cards were compromised during the breach, putting millions of cardholders’ information at risk. The settlement set aside by Target would have



Zerbaxa Labels Cause Confusion Over Dosages

5/21/2015 The FDA announced yesterday that it is warning healthcare professionals of potential problems with Zerbaxa (ceftolozane and tazobactam). Apparently, the Zerbaxa labels cause confusion over dosages. The risk stems from the vial label being approved with each individual active ingredients’ strength listed (e.g. 1 g/0.5 g). The product is not dosed like that, though,


FDA Posted an Alert Regarding Hospira’s LifeCare PCA3 and PCA5 Infusion Pumps

5/21/2015 Earlier this month, the FDA posted an alert regarding Hospira’s LifeCare PCA3 and PCA5 infusion pumps. The computerized systems are used to continuously deliver anesthetic or therapeutic drugs and can be programmed remotely over a hospital’s Ethernet or wireless service. Both Hospira and the FDA learned of certain security vulnerabilities in Hospira’s PCA3 and


SGLT2 Drugs Have Negative History with FDA

  5/21/2015 Quite surprising to me, I found that SGLT2 drugs have negative history with FDA. Not surprising, especially after finding the history, is the warning FDA released earlier this week. It appears that canagliflozin, sold as Invokana, may have created problems in the clinical trials that should have prevented its release. Just as other


TPP: The China Question

5/21/2015 As the Trans-Pacific Partnership (TPP) “fast track” debate continues its push through the congressional gauntlet, my fellow colleague Jay and I have analyzed hundreds of texts and perspectives surrounding the trade deal. We have covered labor, patent and trademarks, mass-torts, environmental concerns, and the highly controversial Investor State Dispute Resolution (ISDS) system, and little


Will Baseball’s Antitrust Exemption Survive the Supreme Court?

5/20/2015 Baseball is a game of eternal youth, and nothing may be more evident of that than listening to 95 year-old retired Supreme Court Justice, John Paul Stevens talk passionately about the future course of the sport. In a May 15th speech in front of the Sports Lawyers Association in Baltimore, Justice Stevens recalled his


Treatment Regimen for SGLT2-Related Ketoacidosis

5/19/2015 Yesterday we wrote about the warning issued by the FDA regarding SGLT2 type 2 diabetes medications. Today, I want to share the treatment regimen for SGLT2-related ketoacidosis. Always consult your physician before making changes in any medication protocol. If you find yourself experiencing any of the symptoms of ketoacidosis, get to the emergency room